article · Pharmaceutics
Sodium valproate, an established antiepileptic medication, promotes hair regeneration by stimulating specific biological pathways and initiating hair growth phases. To repurpose this compound for androgenic alopecia, researchers developed a topical delivery system using nanospanlastics. These carrier vesicles, prepared with non-ionic surfactants and edge activators, were designed to enhance skin permeation and sustain drug release. An optimised formulation produced spherical, deformable nanoscale vesicles that achieved high drug entrapment and sustained release over twelve hours. Laboratory tests confirmed that the formulation markedly improved skin penetration compared to unformulated sodium valproate. In a clinical trial, the nanospanlastics formulation achieved therapeutic outcomes comparable to standard commercial minoxidil lotion while producing fewer adverse effects. These findings show that nanospanlastics offer a viable, safer topical alternative for managing androgenic hair loss.
Androgenic alopecia is a widespread condition with limited topical treatment options, and standard therapies such as minoxidil often cause unwanted side effects. Repurposing an established medication through an engineered topical carrier demonstrates how nanotechnology can improve drug delivery across the skin barrier. This provides a clear direction towards safer, better-tolerated treatments for patients experiencing patterned hair loss.
This work demonstrates an applied topical formulation for androgenic alopecia, relevant to pharmaceutical developers and dermatological product manufacturers. Having advanced through ex vivo testing to a clinical comparison against commercial minoxidil lotion, the formulation sits at an applied and clinically tested stage. Moving towards commercialisation would require broader clinical trials, stability testing, and industrial process development to validate its potential as an alternative to existing topical hair-loss treatments.
AI-generated from the published abstract. Always read the original work before citing.
Sodium valproate (SV) is an antiepileptic drug that is widely used in the treatment of different seizure disorders. The topical SV has a hair regenerative potential through activating the Wnt/β-catenin pathway and anagen phase induction. The aim of the current investigation was to fabricate nanospanlastics of SV for improving its dermal delivery by providing prolonged drug effect and increasing its permeability for treatment of androgenic alopecia (AGA). SV-loaded nanospanlastics were formulated according to 2<sup>3</sup> factorial design by ethanol injection method using a non-ionic surfactant (Span 60) and edge activators (EAs), such as Tween 80 and Cremophor RH 40, to explore the influence of different independent variables on entrapment efficiency (EE%) and percentage drug released after 12 h (Q<sub>12h</sub>) in order to choose the optimized formula using Design-Expert software. The optimized formula (F8) appeared as spherical deformable vesicles with EE% of 90.32 ± 2.18% and Q<sub>12h</sub> of 90.27 ± 1.98%. F8 exhibited significant improvement of ex vivo permeation than free SV. The clinical study exhibited no comparable difference between F8 and marketed minoxidil lotion. However, F8 demonstrates less adverse effects than minoxidil lotion. Nanospanlastics could be a safe and effective method for improving the topical delivery of SV in the management of AGA.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.3390/pharmaceutics12090866
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
